Skip to main content

Annual Reports in Medicinal Chemistry

  • 1st Edition, Volume 34 - August 30, 1999
  • Latest edition
  • Editors: Annette M. Doherty, William Greenlee, William K. Hagmann, Jacob J. Plattner, David Robertson, George L. Trainor, Winnie W. Wong
  • Language: English

Annual Reports in Medicinal Chemistry continues to strive to provide timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emergi… Read more

Purchase options

Sorry, this title is not available for purchase in your country/region.

World Book Day celebration

Where learning shapes lives

Up to 25% off trusted resources that support research, study, and discovery.

Description

Annual Reports in Medicinal Chemistry continues to strive to provide timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences which are expected to provide the basis for entirely new future therapies.Volume 34 retains the familiar format of previous volumes, this year with 33 chapters. Sections I-IV are disease-oriented and generally report on specific medicinal agents with updates from Volume 33 on antithrombotics, neurokinin receptor antagonists, anticoagualants, and new antibacterials. As in past volumes, annual updates have been limited to only the most active areas of research in favor of specifically focused and mechanistically oriented chapters, where the objective is to provide the reader with the most important new results in a particular field.Sections V and VI continue to emphasize important topics in medicinal chemistry, biology, and drug design as well as the critical interfaces among these disciplines. This volume concludes with To Market, To Market--a chapter on NCE and NBE introductions worldwide in 1998, a chapter on pharmagenomics, and finally one on malaria as a third world disease in need of a first world drug development.

Readership

Medicinal, pharmaceutical, and organic chemists.

Table of contents

Section Editor: D.W. Robertson, Central Nervous System Diseases. Section Editor: W.J. Greenlee, Cardiovascular and Pulmonary Diseases. Section Editor: J.J. Plattner, Cancer and Infectious Diseases. Section Editor: W.K. Hagmann, Immunology, Endocrinology, and Metabolic Diseases. Section Editor: W.W. Wong, Topics in Biology. G.L. Trainor, Topics in Drug Design and Discovery. Section Editor: A.M. Doherty, Trends and Perspectives.


D.A. Evrard and B.L. Harrison, Recent Approaches to Novel Antidepressant Therapy. J.R. McCarthy, S.C. Heinrichs, and D.E. Grigoriadis, Recent Progress in Corticotropin-Releasing Factor Receptor Agents. C.E. Augelli-Szafran, L.C. Walker, and H. LeVine III, ß-Amyloid as a Target for Alzheimer's Disease Therapy. A.W Stamford and E.M. Parker, Recent Advances in the Development of Neuropeptide Y Receptor Antagonists. K.S. Takaki and J.R. Epperson, Pharmacological Interventions in the Sleep Process. C. Swain and N.M.J. Rupniak, Progress in the Development of Neurokinin Antagonists.

Product details

  • Edition: 1
  • Latest edition
  • Volume: 34
  • Published: August 30, 1999
  • Language: English

About the editors

AD

Annette M. Doherty

Affiliations and expertise
Pfizer Global R&D, Sandwich Laboratories, United Kingdom

WH

William K. Hagmann

Affiliations and expertise
Parke-Davis Pharmaceutical Research

DR

David Robertson

Affiliations and expertise
Clinical Research Center, Vanderbilt University, Nashville, Tennessee, U.S.A.

View book on ScienceDirect

Read Annual Reports in Medicinal Chemistry on ScienceDirect